MedTrace Logo

Tiotropium for Smoking Asthmatics Study

NCT00546234 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-05-26

No results posted yet for this study

Summary

The study's research questions concern the appropriateness of use of tiotropium for patients with asthma who are current smokers. It is suggested that patients with asthma who smoke, may in fact share similarities with patients with chronic obstructive pulmonary disease (COPD). Because of this, the study will determine whether this sub-group of patients would in fact benefit from therapy currently approved and marketed for COPD patients.

Conditions

Interventions

DRUG

tiotropium

18 mcg daily via Handihaler

DRUG

long acting beta agonist

Turbohaler, 6 \& 12 mcg

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Irvin Mayers, MD, FRCPC · University of Alberta

  • Darcy Marciniuk, MD · University of Saskatchewan

  • Dilini Vethanayagam, MD · University of Alberta

  • Harissios Vliagoftis, MD · Unviersity of Alberta

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546234 on ClinicalTrials.gov